FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits

AstraZeneca (NYSE:AZN) presented key data on the use of FARXIGA (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June 22-26, 2018.

As quoted in the press release:

These studies reinforce the use of dapagliflozin as a treatment option to help improve glycemic control when used with the DPP-4 inhibitor ONGLYZA^® (saxagliptin) versus older treatment options (insulin, sulfonylurea)in patients with T2D. Data investigating the impact of dapagliflozin across patients with a spectrum of cardiovascular (CV) risks were also presented to help further the scientific understanding of the effects of SGLT-2 inhibitors (SGLT-2i) on CV events. In addition, new data investigating dapagliflozin in T1D was also presented.

Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development, AstraZeneca said: “As demonstrated by the broad data on Farxiga featured at ADA, we are firmly committed to addressing the complex unmet needs of people affected by diabetes, of whom many have interrelated CV risks. Through our completed and ongoing research with Farxiga, we’re proud to have developed a highly representative clinical program that we believe will help change clinical practice for diverse patient populations where there remains a need for earlier and more aggressive treatment approaches with SGLT-2 inhibitors.”

Click here to read the full press release.